[
    {
        "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_2089",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_2089"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB00969"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "\"Do not initiate in patients with constipation ( 4.1  History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment ( 4.2  Concomitant use of fluvoxamine ( 4.3 Alosetron hydrochloride tablets  should not be initiated  [see Warnings and Precautions ( 5.1 Alosetron hydrochloride tablets are contraindicated in patients with a history of the following:    chronic or severe constipation or sequelae from constipation intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state Crohn's disease or ulcerative colitis diverticulitis severe hepatic impairment Concomitant administration of alosetron hydrochloride tablets with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold  [see Drug Interactions ( 7.1\""
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/MedicalContraindication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB00969",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "LnC3Emo87wUNfcb0vhs1TD0thVmLqipYJ87sKmsfDwzY82hqp+XGUmTeamNruYc6kgpS/azVEIg0Fp3ncUOtpiiCWMRk0Qh4Pz1ZCsBb9F7MqpILtS76mETqoG2Am7LzMaA85GkVjT86Lo4JW9NKigf6udU9Nk8GZZ9BBDuU1W0="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-08-23T18:51:56.157+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
                    }
                ]
            }
        ]
    }
]